Neurological symptoms associated with COVID-19, from losing the sense of smell to stroke, are linked to a six-fold higher risk of dying as a result of coronavirus.
Infectious disease experts report between 40% and 70% of adults could become infected with coronavirus during the outbreak. In a new interview, Dr. Lipsitch, head of Harvard's T.H. Chan School of Public Health's Center for Communicable Disease Dynamics, discusses the risks and spread potential of COVID-19, and addresses how the infection could impact children's' health.
An international research team revealed the atomic‐level structure of the human peptidase enzyme meprin β (beta).
A new genetic sequencing study reveals SARS-CoV-2, the virus responsible for coronavirus, originated from a single source in Wuhan, China. However, many of the localized cases in the US show Europe as the most likely source of infection. The study also identified a SARS-CoV-2 mutation that has never been seen before, where 81 of the letters have been permanently deleted from the genome. The mutation mirrors a large deletion that occurred during the 2003 SARS outbreak. During the mid-to-late phases of the 2003 SARS infection, the accumulated mutations attenuated the virus, leaving a weakened form of infection that resulted in less severe symptoms.
EIDD-2801, a new antiviral drug, has the potential to treat coronavirus. A new study reveals the drug can prevent severe lung injury in mouse models and cultured human lung cells infected with COVID-19. The drug will soon be ready for human testing.
Injecting extracellular vesicles from healthy mice into mice that had an MS-like disease resulted in the development of a relapse-remitting disease and active CD8+ cells, similar to that seen in human patients with multiple sclerosis. Examining the EVs in mice and humans with MS, researchers identified they contained fibrinogen, a protein normally associated with blood clotting and wound healing. According to researchers, the EVs with fibrinogen appear to activate the CD8+ immune cells. The findings could help with the development of new treatments for RRMS.